Combined analysis of smoking, TP53, and FGFR3 mutations in tunisian patients with invasive and superficial high-grade bladder tumors

Cancer Investigation

Volumn 27, Issue 10, 2009, Pages 998-1007

  Ouerhani, Slah ^a   Rouissi, Kamel ^a   Kourda, Nadia ^b   Marrakchi, Raja ^a   Bougatef, Karim ^a   Riadh Ben Slama, Mohamed ^b   Sfaxi, Mohamed ^b   Chebil, Mohamed ^b   Ben Jilani, Sarra ^b   Benammar Elgaaied, Amel ^a  

^a FACULTÉ DES SCIENCES DE TUNIS   (Tunisia)

^b CHARLES NICOLLE HOSPITAL   (Tunisia)

Author keywords

Bladder cancer; FGFR3 mutation; Population; Smoking; Tp53 mutation; Tunisia

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; PROTEIN P53;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER TUMOR; CANCER INVASION; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SMOKING; TOBACCO;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; CARCINOMA; EXONS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ODDS RATIO; PHENOTYPE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; RISK ASSESSMENT; RISK FACTORS; SMOKING; TUMOR SUPPRESSOR PROTEIN P53; TUNISIA; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 70450214466     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357900902849707     Document Type: Article

References (38)

1. Greenlee, R.T.; Hill-Harmon, M.B.; Murray, T.; Thun, M. Cancer statistics 2001. CA Cancer J Clin 2001, 51, 15-36.
2. Herr, H.W. Tumor progression and survival of patients with highgrade, noninvasive papillary (TaG3) bladder tumors: 15-year outcome. J Urol 2000, 163, 60-62.
3. Zeegers, M.P.; Tan, F.E.; Dorant, E.; Van Den Brandt, P.A. The impact of characteristics of cigarette smoking on urinary tract cancer risk: A meta-analysis of epidemiologic studies. Cancer 2000, 89, 630-639.
4. Thompson, I.M.; Peek, M.; Rodriguez, F.R. The impact of cigarette smoking on stage, grade and number of recurrences of transitional cell carcinoma of the bladder. J Urol 1987, 137, 401-403.
5. Pfeifer, G.P.; Denissenko, M.F.; Olivier, M.; Tretyakova, N.; Hecht, S.S.; Hainaut, P. Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers. Oncogene 2002, 21, 7435-7451.
6. Feng, Z.; Hu, W.; Rom, W.N.; Beland, F.A.; Tang, M.S. 4- aminobiphenyl is a major etiological agent of human bladder cancer: evidence from its DNA binding spectrum in human p53 gene. Carcinogenesis 2002, 23, 1721-1727.
7. Florl, A.R.; Loewer, R.; Schmitz-Dräger, B.J.; Schulz, W.A. DNA methylation and expression of L1 LINE and HERV-K provirus sequences in urothelial and renal cell carcinoma. Br J Cancer 1999, 80, 1312-1321.
8. Cappellen, D.; De Oliveira, C.; Ricol, D.; De Medina, S.; Bourdin, J.; Sastre-Garau, X.; Chopin, D.; Thiery, J.P.; Radvanyi, F. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999, 23, 18-20.
9. Sidransky, D.; Von Eschenbach, A.; Tsai, Y.C.; Jones, P.; Summerhayes, I.; Marshall, F.; Paul, M.; Green, P.; Hamilton, S.R.; Frost, P. Identification of p53 gene mutations in bladder cancers and urine samples. Science 1991, 252, 706-709.
10. Berggren, P.; Steineck, G.; Adolfsson, J.; Hansson, J.; Jansson, O.; Larsson, P.; Sandstedt, B.; Wijkstrom, H.; Hemminki, K. p53 mutations in urinary bladder cancer. Br J Cancer 2001, 84, 1505-1511.
11. Van Rhijn, B.W.; Van der Kwast, T.H.; Vis, A.N.; Kirkels, W.J.; Boev́e, E.R.; Jöbsis, A.C.; Zwarthoff, E.C. FGFR3 and p53 characterize alternative genetic pathway in the pathogenesis of urothelial cell carcinoma. Cancer Res 2004, 64, 1911-1914.
12. Soussi, T.; B́eroud, C. Assessing TP53 status in human tumors to evaluate clinical outcome. Nat Rev Cancer 2001, 1, 233-240.
13. Pluquet, O.; Hainaut, P. Genotoxic and nongenotoxic pathways of p53 induction. Cancer Lett 2001, 174, 1-15.
14. Van Oijen, M.G.; Slootweg, P.J. Gain-of-function mutations in the tumor suppressor gene p53. Clin Cancer Res 2000, 6, 2138-2145.
15. Sigal, A.; Rotter, V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000, 60, 6788-6793.
16. Soussi, T.; Dehouche, K.; Beroud, C. p53 website and analysis of p53 gene mutations in human cancer: Forging a link between epidemiology and carcinogenesis. Hum Mutat 2000, 15, 105-113. (Pubitemid 30036177)
17. Hainaut, P.; Pfeifer, G.P. Patterns of p53 G>T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 2001, 22, 367-374.
18. Hussain, S.P.; Harris, C.C. p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutat Res 1999, 428, 23-32.
19. Bakkar, A.A.; Wallerand, H.; Radvanyi, F.; Lahaye, J.B.; Pissard, S.; Lecerf, L.; Kouyoumdjian, J.C.; Abbou, C.C.; Pairon, J.C.; Jaurand, M.C.; Thiery, J.P.; Chopin, D.K.; DeMedina, S.G. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003, 63, 8108-8112.
20. Herńandez, S.; Ĺopez-Knowles, E.; Lloreta, J.; Kogevinas, M.; Jaramillo, R.; Amoŕos, A.; Tard́on, A.; Garća-Closas, R.; Serra, C.; Carrato, A.; Malats, N.; Real, F.X. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Clin Cancer Res 2005, 11, 5444-5450.
21. Xu, X.; Stower,M.J.; Reid, I.N.; Garner, R.C.; Burns, P.A. A hotspot for p53 mutation in transitional cell carcinoma of the bladder: Clues to the etiology of bladder cancer. Cancer Epidemiol Biomarkers Prev 1997, 6, 611-616.
22. Moore, L.E.; Smith, A.H.; Eng, C.; De Vries, S.; Kalman, D.; Bhargava, V.; Chew, K.; Ferreccio, C.; Rey, O.A.; Hopenhayn, C.; Biggs, M.L.; Bates,M.N.;Waldman, F.M. p53 alterations in bladder tumors from arsenic and tobacco exposed patients. Carcinogenesis 2003, 24, 1785-1791.
23. Bernardini, S.; Adessi, G.L.; Chezy, E.; Billerey, C.; Carbillet, J.P.; Bittard, H. Influence of cigarette smoking on P53 gene mutations in bladder carcinomas. Anticancer Res 2001, 21, 3001-3004.
24. Schroeder, J.C.; Conway, K.; Li, Y.; Mistry, K.; Bell, D.A.; Taylor, J.A. p53 mutations in bladder cancer: evidence for exogenous versus endogenous risk factors. Cancer Res 2003, 63, 7530-7538.
25. Givol, D.; Eswarakumar, V.P.; Lonai, P. Molecular and Cellular Biology of FGF Signalling in the Molecular Basis of Clinical Disorders of Morphogenesis. Oxford: Oxford University Press, 2003.
26. Webster, M.K.; Donoghue, D.J. FGFR activation in skeletal disorders: too much of a good thing. Trends Genet 1997, 13, 178-182.
27. Kannan, K.; Givol, D. FGF receptor mutations: dimerization syndromes, cell growth suppression, and animal models. IUBMB Life 2000, 49, 197-205.
28. Billerey, C.; Chopin, D.; Aubriot-Lorton, M.H.; Ricol, D.; Gil Diez de Medina, S.; Van Rhijn, B.; Bralet, M.P.; Lefrere-Belda, M.A.; Lahaye, J.B.; Abbou, C.C.; Bonaventure, J.; Zafrani, E.S.; Van der Kwast, T.; Thiery, J.P.; Radvanyi, F. Frequent FGFR3 mutations in papillary noninvasive bladder (pTa) tumors. Am J Pathol 2001, 158, 1955-1959.
29. Hart, K.C.; Robertson, S.C.; Kanemitsu, M.Y.; Meyer, A.N.; Tynan, J.A.; Donoghue, D.J. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene 2000, 19, 3309-3320.
30. Wallerand, H.; Bakkar, A.A.; De Medina, S.G.; Pairon, J.C.; Yang, Y.C.; Vordos, D.; Bittard, H.; Fauconnet, S.; Kouyoumdjian, J.C.; Jaurand, M.C.; Zhang, Z.F.; Radvanyi, F.; Thiery, J.P.; Chopin, D.K. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: Contribution of exogenous versus endogenous carcinogens. Carcinogenesis 2005, 26, 177-184.
31. Van Oers, J.M.; Lurkin, I.; Van Exsel, A.J.; Nijsen, Y.; Van Rhijn, B.W.; Van der Aa, M.N.; Zwarthoff, E.C. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3mutations in bladder cancer and voided urine. Clin Cancer Res 2005, 11, 7743-7748.
32. O'Gorman, T.W.; Woolson, R.F. The effect of category choice on the odds ratio and several measures of association in case-control studies. Commun Stat 1993, 22, 1157-1171.
33. Bartkova, J.; Horejsi, Z.; Koed, K.; Kramer, A.; Tort, F.; Zieger, K.; Guldberg, P.; Sehested, M.; Nesland, J.M.; Lukas, C.; Orntoft, T.; Lukas, J.; Bartek, J. DNA damage response as a candidate anticancer barrier in early human tumorigenesis. Nature 2005, 434, 864-870.
34. Van Rhijn, B.W.; Vis, A.N.; Van der Kwast, T.H.; Kirkels,W.J.; Radvanyi, F.; Ooms, E.C.; Chopin, D.K.; Boev́e, E.R.; Jöbsis, A.C.; Zwarthoff, E.C. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 2003, 21(10), 1912-1921.
35. D'Avanzo, B.; Negri, E.; La Vecchia, C. Cigarette smoking and bladder cancer. Eur J Cancer 1990, 26, 714-718.
36. Brennan, P.; Bogillot, O.; Cordier, S.; Greiser, E.; Schill,W.; Vineis, P.; Lopez-Abente, G.; Tzonou, A.; Chang-Claude, J.; Bolm-Audorff, U.; Jöckel, K.H.; Donato, F.; Serra, C.; Wahrendorf, J.; Hours, M.; Mannetje, A.T.; Kogevinas, M.; Boffetta, P. Cigarette smoking and bladder cancer in men: A pooled analysis of 11 case-control studies. Int J Cancer 2000, 86, 289-294.
37. Olivier, M.; Eeles, R.; Hollstein, M.; Khan, M.A.; Harris, C.C.; Hainaut, P. The IARC TP53 database: new online mutation analysis and recommendations to user. Hum Mutat. 2002, 19, 607-614.
38. Ryk, C.; Berggren, P.; Kumar, R.; Hemminki, K.; Larsson, P.; Steineck, G.; Lambert, B.; Hou, S.M. Influence of GSTM1, GSTT1, GSTP1 and NAT2 genotypes on the p53 mutational spectrum in bladder tumours. Int J Cancer 2005, 113, 761-768.